Last Updated : November 20, 2015
Details
FilesGeneric Name:
Mepolizumab
Project Status:
Complete
Therapeutic Area:
Asthma, severe eosinophilic
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
Nucala
Project Line:
Reimbursement Review
Project Number:
SR0461-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Submission Type:
Initial
Indications:
Asthma, severe eosinophilic
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Files
Last Updated : November 20, 2015